Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121338882 | 12133888 | 2 | F | 20160906 | 20160301 | 20160909 | EXP | VE-GLAXOSMITHKLINE-VE2016GSK028682 | GLAXOSMITHKLINE | 0.00 | F | Y | 84.00000 | KG | 20160909 | CN | VE | VE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121338882 | 12133888 | 1 | PS | SERETIDE | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 2 PUFF(S), QD | U | 21077 | 2 | DF | INHALATION POWDER | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 121338882 | 12133888 | 1 | Asthma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 121338882 | 12133888 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 121338882 | 12133888 | Asthmatic crisis | |
| 121338882 | 12133888 | Chest discomfort | |
| 121338882 | 12133888 | Cough | |
| 121338882 | 12133888 | Dyspnoea | |
| 121338882 | 12133888 | Haemoptysis | |
| 121338882 | 12133888 | Insomnia | |
| 121338882 | 12133888 | Product availability issue | |
| 121338882 | 12133888 | Therapy cessation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |